

In the Claims:

Please cancel claims 1-21. Please add new claims 22-42.

1-21. (Canceled.)

22. (New) A method for the treatment of depression or anxiety in a human in need thereof comprising administering a therapeutically effective combination comprising a dose of each of components:

- a) paroxetine or a physiologically acceptable salt or solvate thereof; and
- b) 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or a pharmaceutically acceptable salt or solvate thereof,

wherein said dose of each component is lower than normally expected to produce an effective therapeutic response in the treatment of depression or anxiety in said human, as demonstrated in the gerbil social interaction model.

23. (New) The method as claimed in claim 22 wherein said component a) is paroxetine hydrochloride hemihydrate salt and said component b) is 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide methanesulphonate salt.

24. (New) The method as claimed in claim 22, wherein said dose of component a) is from 1 to 10 mg (measured as the free base).

25. (New) The method as claimed in claim 22, wherein said dose of component a) is from 3.5 to 7.5 mg (measured as the free base).

26. (New) The method as claimed in claim 22, wherein said dose of component b) is from 1 to 15 mg (measured as the free base).

27. (New) The method as claimed in claim 22, wherein said dose of component b) is from 5 to 15 mg (measured as the free base).

28. (New) The method as claimed in claim 22, wherein said dose of component b) is from 7 to 15 mg (measured as the free base).
29. (New) The method as claimed in claim 22, wherein said dose of component a) is from 1 to 10 mg (measured as the free base) and said dose of component b) is from 1 to 15 mg (measured as the free base).
30. (New) The method as claimed in claim 22, wherein said dose of component a) is from 1 to 10 mg (measured as the free base) and said dose of component b) is from 5 to 15 mg (measured as the free base).
31. (New) The method as claimed in claim 22, wherein said dose of component a) is from 1 to 10 mg (measured as the free base) and said dose of component b) is from 7 to 15 mg (measured as the free base).
32. (New) The method as claimed in claim 22, wherein said dose of component a) is from 3.5 to 7.5 mg (measured as the free base) and said dose of component b) is from 1 to 15 mg (measured as the free base).
33. (New) The method as claimed in claim 22, wherein said dose of component a) is from 3.5 to 7.5 mg (measured as the free base) and said dose of component b) is from 5 to 15 mg (measured as the free base).
34. (New) The method as claimed in claim 22, wherein said dose of component a) is from 3.5 to 7.5 mg (measured as the free base) and said dose of component b) is from 7 to 15 mg (measured as the free base).
35. (New) The method as claimed in claim 22, wherein said dose of component a) is 7.5 mg (measured as the free base) and said dose of component b) is 15 mg (measured as the free base).

36. (New) The method as claimed in claim 22, wherein said dose of component a) is 3.75 mg (measured as the free base) and said dose of component b) is 15 mg (measured as the free base).
37. (New) The method as claimed in claim 22, wherein said dose of component a) is 7.5 mg (measured as the free base) and said dose of component b) is 7.5 mg (measured as the free base).
38. (New) The method as claimed in claim 22, wherein said dose of component a) is 3.75 mg (measured as the free base) and said dose of component b) is 7.5 mg (measured as the free base).
39. (New) The method as claimed in claim 22, wherein said combination is a unitary dosage form.
40. (New) A pharmaceutical formulation comprising a dose of each of components:
- a) paroxetine or a physiologically acceptable salt or solvate thereof; and
 - b) 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide or a pharmaceutically acceptable salt or solvate thereof,
- wherein said dose of each component is lower than normally expected to produce an effective therapeutic response in the treatment of depression or anxiety in said human, as demonstrated in the gerbil social interaction model.
- together with one or more pharmaceutically acceptable carriers or excipients.
41. (New) The pharmaceutical formulation as claimed in claim 40, wherein said component a) is paroxetine hydrochloride hemihydrate salt and said component b) is 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide methanesulphonate salt.

PB60212USw

42. (New) The pharmaceutical formulation as claimed in claim 40 comprising:

- a) from 3.5 to 7.5 mg (measured as the free base) of paroxetine hydrochloride hemihydrate salt and
- b) from 7 to 15 mg (measured as the free base) of 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide methanesulphonate salt.